To view this email as a web page, click here.
 
Large PBM covers 2 migraine treatments, excludes another
CVS Health's addition of 2 new migraine prevention drugs to its list of covered drugs could impact sales of a third migraine treatment.
Read more
 
FDA approves cabozantinib for treatment-experienced patients with aggressive liver cancer
A treatment recently approved by FDA to treat liver cancer is already available on the market.
Read more
 
Three effects of the government shutdown on biosimilar development
From our sister brand, Managed Healthcare Executive: How did the government shutdown interfere with biosimilar development?
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.